NCT05705167终止2 期
A Multicentre, Open Label, Randomised, Controlled, Basket, Pragmatic, Phase II, Clinical and Translational Study to Determine the Efficacy and Safety of Plitidepsin Versus Control in Immunocompromised Adult Patients With Symptomatic COVID-19 Requiring Hospital Care
PharmaMar44 个研究点 分布在 11 个国家目标入组 37 人开始时间: 2023年4月19日最近更新:
适应症
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 37
- 试验地点
- 44
- 主要终点
- One-month All-cause Mortality Rate
研究概览
简要总结
The primary objective of this study is to evaluate efficacy of plitidepsin in pre-specified groups of immunocompromised patients with symptomatic COVID-19 requiring hospital care versus control in terms of mortality.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent obtained prior to initiation of any study-specific procedures and study treatment.
- •Participant aged ≥18 years.
- •Participant diagnosed COVID-19, with the following characteristics:
- •A regulatory-approved test, collected no more than 3 days prior to study randomisation, with either a Ct value ≤30 or a positive antigen test.
- •Presence of any of the selected signs/symptom listed in the COVID-19 signs/symptoms checklist within the last 24 hours.
- •Participant already admitted or requiring hospital care for symptomatic COVID-19, for which at least one antiviral has failed or cannot be used (i.e., contraindication, absence of labelled indication, guidelines or drug unavailability), after a minimum washout period of 24 hours for small molecules (e.g., remdesivir, molnupiravir, nirmaltrevir, ritonavir) and 5 days for antiviral monoclonal antibodies (e.g., tixagevimab + cilgavimab) or convalescent plasma.
- •Adequate bone marrow, liver, kidney, and metabolic function, defined by the following tests performed at local laboratory:
- •Absolute neutrophil count ≥500/mm^3 (0.5 x 109/L).
- •Platelet count ≥ 50 000/mm3 (50 x 109/L).
- •Alanine transaminase (ALT) ≤3 x upper limit of normal (ULN) (≤5 x ULN if preexistent liver involvement by the underlying disease).
- •Serum bilirubin ≤1.5 x ULN (or direct bilirubin <1.5 x ULN when total bilirubin is above ULN).
- •Estimated glomerular filtration rate ≥30 mL/min (CKD-EPI Creatinine Equation [2021]).
- •Females of child-bearing potential must have a negative serum or urine pregnancy test by local laboratory at screening and must be non-lactating.
- •Females of child-bearing potential and fertile males with partners of child-bearing potential must use contraceptive methods as specified in the protocol.
- •Group-specific inclusion criteria:
- •Group 1 - Patients receiving, within the last 30 days, immune-suppressive therapy due to haematopoietic or organ transplantation.
- •Group 2 - Participants receiving B-cell depleting therapies within the last 6 months (with the exception of CAR-T cell therapy for which time restriction is not applicable).
- •Group 3 - Participants receiving, within the last 30 days, other immune-suppressive therapies.
- •Group 4 - Other situations with immunodeficiency.
- •Primary immune deficiencies.
- •Human immunodeficiency virus (HIV) infection, with CD4^+ T lymphocyte < 200 cells/μL in the last month.
- •Radiation therapy within the last 3 months- requires documentation of ALC < 500 cells/μL.
- •Haematological neoplasia or myelodysplasia not currently receiving any therapy.
- •Other situations with a documentation of ALC < 500 cells/μL.
排除标准
- •Evidence of critical illness.
- •Any of the following cardiac conditions or risk factors:
- •Cardiac infarction or cardiac surgery episode within the last month.
- •History of known congenital QT prolongation.
- •Known structural cardiomyopathy with abnormal left ventricular ejection fraction (LVEF) (<50%).
- •Current clinical evidence of heart failure or acute cardiac ischaemia (New York Heart Association (NYHA) class III-IV).
- •Hypersensitivity to the active ingredient or any of the excipients (mannitol, macrogolglycerol hydroxystearate, and ethanol) or contraindication to receive dexamethasone, antihistamine H1/H2, or anti-serotoninergic 5HT3 agents.
- •Females who are pregnant or breast-feeding.
- •Females and males with partners of child-bearing potential who are not using at least 1 protocol-specified method of contraception.
- •Any situation currently requiring increasing needs of immune-suppressive agents.
- •Any other clinically significant medical condition or laboratory abnormality that, in the opinion of the investigator, would jeopardise the safety of the participant or potentially impact on participant compliance or the safety/efficacy observations in the study.
- •Participation in another clinical study involving an investigational drug within 30 days prior to screening.
研究组 & 干预措施
Plitidepsin 2.5 mg
Experimental
Best standard care (as per applicable local, institutional, national, supranational COVID-19 treatment guidelines) and plitidepsin (administered as a 60-minute intravenous (IV) infusion, every 24 hours for 3 consecutive days, at a dose of 2.5 mg) will be administered to participants of the following groups:
- Group 1 - Participants receiving immune-suppression due to haematopoietic or organ transplantation.
- Group 2 - Participants receiving B-cell depleting therapies.
- Group 3 - Participants receiving other immune-suppressive therapies.
- Group 4 - Other situations with immune deficiencies.
干预措施: Plitidepsin (Drug)
结局指标
主要结局
One-month All-cause Mortality Rate
时间窗: Day 1 to Day 30 (±2)
In the event of the participant initiating another non-protocol therapy, 1-month all-cause mortality rate was evaluated regardless of initiation of new non-protocol therapy.
次要结局
- Time to Confirmed Negativisation in SARS-CoV-2 Antigen Test or Real Time Polymerase Chain Reaction (RT-PCR) Cycle Threshold (Ct) > 30(Day 1 to Day 60 (±3))
- Time to Sustained End of COVID-related Hospital Care(Day 1 to Day 60 (±3))
- Time to Sustained Improvement and Resolution of Selected COVID-19 Signs/Symptoms(Day 1 to Day 60 (±3))
- Number of Participants in Each Category of the World Health Organization (WHO) Clinical Progression Scale (CPS)(Days 4 (±1), 8 (±1), 15 (±1), 30 (±2), and 60 (±3))
- Number of Participants Requiring Oxygen Therapy(Days 4 (±1), 8 (±1), 15 (±1), 30 (±2), and 60 (±3))
- Time to Sustained Discontinuation of Oxygen Supplementation(Day 1 to Day 60 (±3))
- Number of Participants Who Experience a Treatment-emergent Adverse Event (TEAE)(Day 1 to Day 60 (±3))
研究者
研究点 (44)
Loading locations...
相似试验
进行中（未招募）
2 期
Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)Post COVID-19 ConditionLong COVID SyndromePersistent COVID-19Persistent COVID ConditionLong COVIDNCT06766825Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia90
已完成
1 期
Study of Plitidepsin in Combination With Sorafenib or Gemcitabine in Patients With Advanced Solid Tumors or LymphomasAdvanced Solid TumorsLymphomasNCT00788099PharmaMar45
终止
2 期
A Study of Plitidepsin in Patients With Relapsed or Refractory Angioimmunoblastic T-cell LymphomaLymphomaNCT03070964PharmaMar14
终止
2 期
Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and LenalidomideMultiple MyelomaNCT03117361PharmaMar10
终止
3 期
Tislelizumab Monotherapy Versus Salvage Chemotherapy for Relapsed/Refractory Classical Hodgkin LymphomaClassical Hodgkin LymphomaNCT04486391BeiGene3